Inflammatory bowel disease. Pathophysiology and medical treatment;Chronisch-entzundliche Darmerkrankungen. Pathophysiologie und medikamentose Therapie

Radiologe

Volumn 38, Issue 1, 1998, Pages 3-7

  Von Ritter, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chronic inflammatory bowel disease; Crohn's disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIOXIDANT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; CYTOKINE ANTIBODY; FISH OIL; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CROHN DISEASE; ENTERITIS; HUMAN; MAINTENANCE THERAPY; SLOW RELEASE FORMULATION; ULCERATIVE COLITIS; CELL MEMBRANE PERMEABILITY; DRUG EFFECT; EPITHELIUM; LYMPHATIC SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; CELL MEMBRANE PERMEABILITY; COLITIS, ULCERATIVE; CROHN DISEASE; EPITHELIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC SYSTEM; TREATMENT OUTCOME;

EID: 0031603333     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001170050316     Document Type: Article

References (45)

1. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioni M (1996) Effect of an entericcoated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334: 1557-1560
2. Bernstein LH, Frank MS, Brandt LJ, Boley SJ (1980) Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79:357-365
3. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ (1987) Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 93: 480-489
4. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343: 1249-1252
5. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre J-P (1996) Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 110: 424-431
6. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P (1997) Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112: 1475-1481
7. Duchmann R, Neurath M, Märker-Hermann E, Meyer zum Büschenfelde K-H (1997) Immune responses towards intestinal bacteria - cur-rent concepts and future perspectives. Z Gastroenterol 35: 337-346
8. Elson CO, Sartor RB, Tennyson GS, Riddel RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367
9. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M et al (1995) Methotrexate for the treatment of Crohn's disease. N Engl J Med 332: 292-297
10. Fiocchi C (1993) Cytokines and animal models: a combined path to inflammatory bowel disease pathogenesis. Gastroenterology 104: 1202-1219
11. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L-G, Persson T, Canadian Inflammatory Bowel Disease Study Group (1994) Oral budesonide for active Crohn's disease. N Engl J Med 331: 836-841
12. Greenberg GR, Martin F, Feagan BG, Sutherland LR, Thomson ABR, Williams CN, Nilsson L-G, Persson T, The Canadian Inflammatory Bowel Disease Study Group (1996) Oral budesonide as maintenance treatment for Crohn's disease: a placebocontrolled, dose-ranging study. Gastroenterology 110: 45-51
13. Hanauer SB (1994) Nicotine for colitis - the smoke has not yet cleared. N Engl J Med 330: 856-857
14. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA, Pentasa Crohn's Disease Compassionate Use Study Group (1993) Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol 88: 1343-1351
15. Hollander D, Constance MV, Brettholz E, Petersen GM, Delahunty T, Rotter JI (1986) Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 105: 883-885
16. Kagnoff MF (1993) Immunology of the intestinal tract. Gastroenterology 105: 1275-1280
17. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI (1989) Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97:927-931
18. Kruis W, Schütz E, Stolte M, Fixa B, Fric P, Judmaier G (1995) Double-blind comparison between mesalamine (Salofalk) and a preparation of viable E. coli Nissle 1917 (Mutaflor) for maintenance therapy of ulcerative colitis. Gastroenterology 108: A 853
19. Lémann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliant R (1995) Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 9: 557-562
20. Löfberg R, Rutgeerts P, Makhow H, Lamers C, Danielsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H et al (1996) Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 39: 82-86
21. MacPherson BR, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365-375
22. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Jeejeebhoy KN et al (1995) Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 109: 404-413
23. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d'Albasio G, De Simone G, Martini N (1994) Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89: 692-698
24. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A et al (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110: 1416-1421
25. Oriishi T, Sata M, Toyonaga A, Sasaki E, Tanikawa K (1995) Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 36: 891-896
26. Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. Ann Intern Med 122: 132-142
27. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R (1995) Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108: 1617-1621
28. Sandborn WJ (1996) A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-Mercaptopurine, Cyclosporine, and Methotrexate. Am J Gastroenterol 91: 423-433
29. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD (1997) Transdermal nicotine for midly to moderately active ulcerative colitis. Ann Intern Med 126: 364-371
30. Sartor RB (1994) Cyclosporine therapy for inflammatory bowel disease. N Engl J Med 330: 1897-1898
31. Sartor RB, Rath CR, Sellon RK (1996) Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 12: 327-333
32. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, Raedler A (1995) Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 108: 21-33
33. Schütz E (1989) Behandlung von Darmerkrankungen mit Mutaflor. Fortschr Med 107: 599-602
34. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL, Pentasa Crohn's Disease Study Group (1993) Mesalamine capsules for the treatment of active Crohn's disease. Gastroenterology 104: 1293-1301
35. Steinhart AH, Hemphill D, Greenberg GR (1994) Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a metaanalysis. Am J Gastroenterol 89: 2116-2124
36. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32: 1071-1075
37. Sutherland LR, May GR, Shaffer EA (1993) Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118: 540-549
38. The Mesalamine Study Group (1996) An oral preparation of mesalamine and as longterm maintenance therapy for ulcerative colitis. Ann Intern Med 124: 204-211
39. Ursing B, Alm T, Bárány F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Järnerot G, Krause U, Krook A et al (1982) A comparative study of metronidazole and sulfasalazine for active Crohn's disease study in Sweden. Gastroenterology 83: 550-562
40. van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135
41. Von Ritter C (1991) The role of increased intestinal permeability in inflammatory bowel disease. In: Goebell (ed) Inflammatory bowel disease: current status and future approach. Kluwer, pp 45-48
42. Von Ritter C, Grisham MB, Granger DN (1989) Sulfasalazine metabolites and dapsone attenuate formyl-Methionyl-Leucyl-Phenylanalanine-induced mucosal injury in rat ileum. Gastroenterology 96: 811-816
43. Von Ritter C, Grisham MB, Höllwarth M, Inauen W, Granger DN (1989) Neutrophilderived oxidants mediate formyl-Methionyl-Leucyl-Phenylalanine-induced increases in mucosal permeability in rats. Gastroenterology 97: 778-780
44. Von Ritter C, Sekizuka E, Grisham MB, Granger DN (1988) The chemotactic peptide N-formyl methionine-leucyl-phenylalanine increases mucosal permeability in the distal ileum of the rat. Gastroenterology 95: 651-656
45. Wallace JL, Beck PL (1996) Inflammatory mediators in inflammatory bowel disease. Curr Opin Gastroenterol 12: 334-339